The newly synthesized compounds 7a-e, 8a-d, 9a-c, 12, 15, 18, 20, and 22 were evaluated for their cytotoxicity against HELA cancer cell lines. Additionally, the therapeutic safety of the tested compounds was determined by screening their cytotoxicity on WI38 (normal fibroblast cell line) using Sulforhodamine B (SRB) colorimetric assay. The results revealed that all the tested compounds showed inhibitory activity to the tumor cell lines in a concentration dependent manner. Interestingly, the results represented in Table showed that compounds 15, 20 and 22 were the most active compounds (IC50 value of 35.8 ± 2.68, 37.8 ± 1.98, 23.8 ± 1.72 μg/mL, respectively) against the HELA carcinoma cell line, compared with Doxorubicin reference drug with IC50 value of 10.59 ± 1.03 μg/mL. Moreover, the order of activity against (HELA) cell line was 22 > 15 > 20